CleoDX is developing a blood test for early and accurate ovarian cancer diagnosis using the CXCL10 biomarker. This patented technology has undergone over a decade of research at the Hudson Institute of Medical Research, including two clinical studies with over 500 patients. Cleo holds a worldwide exclusive license for this technology. Their goal is to address the urgent need for better ovarian cancer detection, potentially improving survival rates. Their modular approach will cover various aspects of ovarian cancer detection, including surgical triage, recurrence, high-risk cases, and early-stage screening.
Cleo Diagnostics (ASX: COV)
- Home
- Cleo Diagnostics (ASX: COV)
Here are the latest articles on Cleo Diagnostics (ASX: COV)
CLEO meets with US FDA to develop strategy for ovarian cancer test launch
June 26, 2024
Ovarian cancer diagnostics company Cleo Diagnostics (ASX: COV) has taken a major step towards the US launch of its pre-surgical triage test for ovarian cancer detection. The Company wrapped up an initial pre-submission meeting with the U.S. Food and Drug Administration (FDA), thus setting its regulatory journey in motion. Ovarian cancer is a serious health
Cleo’s ovarian cancer blood test proves more effective than CA125 clinical benchmark and ultrasound
May 29, 2024
A benchmarking study comparing ovarian cancer diagnostics company Cleo Diagnostics (ASX: COV)’s blood test against ultrasound has been published in the scientific journal “Cancers” with positive outcomes. The study found that Cleo’s initial test for the surgical triage market significantly outperforms the current clinical workflows that use Cancer Antigen 125 (CA125) and ultrasound to predict
Cleo Diagnostics progresses ovarian cancer test kits for US, Australia, and EU markets
October 9, 2023
Just two months after it first floated on the ASX, ovarian cancer diagnostics company Cleo Diagnostics (ASX: COV).
IPO Watch: Cleo Diagnostics to go public with ovarian cancer test kits to address 51% survival rate
August 3, 2023
As diseases continue to adapt, the realm of medical diagnostics must intelligently progress to adeptly combat these changes. Timely interventions and treatments are crucial to improve patient outcomes and survival rates. There are approximately 14 medical diagnostics companies listed on the ASX, striving to pioneer the early detection of new diseases and make significant progress
Recent Articles
